Black Diamond Therapeutics (BDTX) Market Capitalization (2020 - 2026)

Black Diamond Therapeutics (BDTX) has reported Market Capitalization for 7 consecutive years, with $106.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization fell 24.67% year-over-year to $106.3 million; the trailing twelve-month figure through Jun 2026 stood at $106.3 million (down 24.67% YoY), and the FY2025 full-year result was $138.8 million, up 14.54% from the prior year.
• Market Capitalization eased to $106.3 million in Q2 2026 per BDTX's latest filing, from $122.1 million in the prior quarter.
• Across five years, Market Capitalization topped out at $266.3 million in Q1 2024 and bottomed at $61.5 million in Q3 2022.
• Historically, Market Capitalization has averaged $142.9 million across 5 years, with a median of $130.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Market Capitalization plunged 88.54% in 2022, then jumped 285.92% in 2024.
• Over 5 years, Market Capitalization stood at $65.6 million in 2022, then jumped by 121.29% to $145.1 million in 2023, then slipped by 16.47% to $121.2 million in 2024, then increased by 14.54% to $138.8 million in 2025, then slipped by 23.46% to $106.3 million in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $106.3 million, $122.1 million, and $138.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.